Looking Ahead: The Next Frontier in ALK+ NSCLC Therapy

Future Directions

• Key Discussion Points:
• Dr Lovly highlighted promising clinical trials that may reshape ALK+ NSCLC treatment sequencing strategies

Notable Expert Insights

• Dr Dietrich provided critical analysis of the CROWN trial data and the implications of matching-adjusted indirect comparisons between different ALK inhibitors for clinical decision-making
• Dr Lovly offered specialized perspective on resistance patterns and mutation-guided therapy selection, particularly incorporating emerging data on investigational agents like NVL-655
• Elizabeth Castronovo contributed valuable real-world experience comparing clinical trial outcomes with observed patient responses and toxicity management approaches
• Mary Grizzard emphasized patient-centered care considerations, highlighting education strategies and practical challenges faced during treatment transitions

The panelists collectively addressed the evolving treatment landscape for ALK+ NSCLC, emphasizing evidence-based approaches to optimize patient outcomes through appropriate therapy selection, sequencing strategies, and adverse event management.